Why Is SUMMIT THERAPEUTICS (SMMT) Stock Up Today?

SMMT stock is up 5.14% at $14.32 in a session marked by positive interim data developments for its lead cancer therapy. The stock opened lower but reversed sharply, closing near its session high. The move follows a key milestone highlighted by a partner and a reiteration of analyst coverage.

What Happened

Summit Therapeutics' shares rose on news that its partner emphasized positive interim data for its lead cancer therapy. This development came amid broader market volatility, as the Nasdaq 100 declined due to inflation concerns. The stock opened at $13.50, a 0.9% gap down from the prior close, but climbed steadily throughout the session. Cantor Fitzgerald reissued its existing stock rating, adding to the backdrop of analyst activity. Meanwhile, the stock was among several big movers highlighted in market coverage, including other health care names.

Insider activity has also been notable, with multiple executives purchasing shares in recent weeks. Co-CEOs Robert Duggan and Mahkam Zanganeh, along with COO and CFO Manmeet Singh Soni, all made purchases within the past month. The most recent insider transactions occurred on June 12, 2026, with total insider buying in the last 90 days reaching $103.6 million.

What The Data Shows

The stock has traded in a range of $12.07 to $29.23 over the past 52 weeks and is currently near its 52-week high, having printed 24 fresh 52-week highs on September 1, 2026. Over the past eight sessions, the stock has gained 3.7%, moving from $13.12 to $13.61 before today’s sharp move. Intraday volume has reached 1.3 million shares, which is 0.2 times the 3-month average. The stock opened below the prior close but surged to a high of $14.36 before settling at $14.32.

What To Watch

The stock’s near-term trajectory will depend on further developments from its lead cancer therapy program and broader market conditions. Investors should monitor any follow-up data releases or analyst updates in the coming weeks.